Literature DB >> 31372254

Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer.

Vincent K Lam1, Jianjun Zhang1.   

Abstract

Entities:  

Year:  2019        PMID： 31372254      PMCID： PMC6626794          DOI： 10.21037/jtd.2019.05.68

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  4 in total

Review 1.  Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.

Authors:  Monika Pradhan; Mathieu Chocry; Don L Gibbons; Boris Sepesi; Tina Cascone
Journal:  Transl Lung Cancer Res       Date:  2021-01

Review 2.  Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.

Authors:  Kamila Wojas-Krawczyk; Tomasz Kubiatowski
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

3.  Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.

Authors:  Milou Schuurbiers; Zhongyun Huang; Senglor Saelee; Manana Javey; Leonie de Visser; Daan van den Broek; Michel van den Heuvel; Alexander F Lovejoy; Kim Monkhorst; Daniel Klass
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 12.469

Review 4.  Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications.

Authors:  Pinhao Fang; Jianfeng Zhou; Zhiwen Liang; Yushang Yang; Siyuan Luan; Xin Xiao; Xiaokun Li; Hanlu Zhang; Qixin Shang; Xiaoxi Zeng; Yong Yuan
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.